{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:15:03Z","timestamp":1784146503708,"version":"3.55.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1007\/s10689-004-9550-2","type":"journal-article","created":{"date-parts":[[2004,10,29]],"date-time":"2004-10-29T21:06:34Z","timestamp":1099083994000},"page":"249-257","source":"Crossref","is-referenced-by-count":55,"title":["Hereditary breast cancer in Jews"],"prefix":"10.1007","volume":"3","author":[{"given":"Wendy S.","family":"Rubinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T et al.Cancer statistics, 2004.CA Cancer J Clin 2004;54(1):8?29.","journal-title":"CA Cancer J Clin"},{"key":"CR2","volume-title":"Quantitative Risk Assessment. Advanced Therapy of Breast Disease","author":"WS Rubinstein","year":"2004","unstructured":"Rubinstein WS, O'Neill SM.Quantitative Risk Assessment. Advanced Therapy of Breast Disease.New York: BC Decker 2004."},{"issue":"2","key":"CR3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ng1095-198","volume":"11","author":"JP Struewing","year":"1995","unstructured":"Struewing JP, Abeliovich D, Peretz T et al.The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.Nat Genet 1995;11(2):198?200.","journal-title":"Nat Genet"},{"issue":"6","key":"CR4","first-page":"1284","volume":"57","author":"LS Friedman","year":"1995","unstructured":"Friedman LS, Szabo CI, Ostermeyer EA et al.Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.Am J Hum Genet 1995;57(6):1284?97.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"CR5","first-page":"189","volume":"57","author":"P Tonin","year":"1995","unstructured":"Tonin P, Serova O, Lenoir G et al.BRCA1 mutations in Ashkenazi Jewish women.Am J Hum Genet 1995;57(1):189.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"CR6","first-page":"1166","volume":"58","author":"DB Berman","year":"1996","unstructured":"Berman DB, Wagner-Costalas J, Schultz DC et al.Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families:a genetic study of 15 185delAG-mutation kindreds.Am J Hum Genet 1996;58(6):1166?76.","journal-title":"Am J Hum Genet"},{"issue":"15","key":"CR7","first-page":"3409","volume":"56","author":"DB Berman","year":"1996","unstructured":"Berman DB, Costalas J, Schultz DC et al.A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.Cancer Res 1996; 56(15):3409?14.","journal-title":"Cancer Res"},{"issue":"3","key":"CR8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJM199601183340302","volume":"334","author":"MG Fitzgerald","year":"1996","unstructured":"Fitzgerald MG, MacDonald DJ, Krainer M et al.Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.N Engl J Med 1996;334(3):143?9.","journal-title":"N Engl J Med"},{"issue":"1","key":"CR9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/ng0596-126","volume":"13","author":"S Neuhausen","year":"1996","unstructured":"Neuhausen S, Gilewski T, Norton L et al.Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.Nat Genet 1996;13(1):126?8.","journal-title":"Nat Genet"},{"issue":"2","key":"CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","volume":"14","author":"BB Roa","year":"1996","unstructured":"Roa BB, Boyd AA, Volcik K, Richards CS.Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.Nat Genet 1996;14(2):185?7.","journal-title":"Nat Genet"},{"issue":"2","key":"CR11","first-page":"188","volume":"14","author":"C Oddoux","year":"1996","unstructured":"Oddoux C, Struewing JP, Clayton CM et al.The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %Nat Genet 1996;14(2):188?90.","journal-title":"The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1 %Nat Genet"},{"issue":"5182","key":"CR12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D et al.A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266(5182):66?71.","journal-title":"Science"},{"issue":"6559","key":"CR13","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/378789a0","volume":"378","author":"R Wooster","year":"1995","unstructured":"Wooster R, Bignell G, Lancaster J et al.Identification of the breast cancer susceptibility gene BRCA2.Nature 1995; 378 (6559):789?92.","journal-title":"Nature"},{"issue":"3","key":"CR14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng0396-333","volume":"12","author":"SV Tavtigian","year":"1996","unstructured":"Tavtigian SV, Simard J, Rommens J et al.The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.Nat Genet 1996;12(3):333?7.","journal-title":"Nat Genet"},{"issue":"6","key":"CR15","first-page":"1457","volume":"57","author":"D Ford","year":"1995","unstructured":"Ford D, Easton DF, Peto J.Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.Am J Hum Genet 1995;57(6):1457?62.","journal-title":"Am J Hum Genet"},{"key":"CR16","first-page":"375","volume-title":"The Breast","author":"HT Lynch","year":"2004","unstructured":"Lynch HT, Marcus JN, Lynch JF et al.Breast cancer genetics: heterogeneity, molecular genetics, and syndrome diagnosis, and genetics counseling.In Bland and Copeland (eds):The Breast. Amsterdam: Elsevier 2004:375?411."},{"issue":"5","key":"CR17","first-page":"1085","volume":"60","author":"CS Richards","year":"1997","unstructured":"Richards CS, Ward PA, Roa BB et al.Screening for 185delAG in the Ashkenazim.Am J Hum Genet 1997;60(5):1085?98.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"CR18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00125817-200209000-00005","volume":"4","author":"LS Lehmann","year":"2002","unstructured":"Lehmann LS, Weeks JC, Klar N, Garber JE.A population-based study of Ashkenazi Jewish women 's attitudes toward genetic discrimination and BRCA1\/2 testing.Genet Med 2002;4 (5):346?52.","journal-title":"Genet Med"},{"key":"CR19","first-page":"2465","volume":"3","author":"WD Foulkes","year":"1997","unstructured":"Foulkes WD, Wong N, Brunet JS et al.Germ-line BRCA1mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer.Clin Cancer Res 1997;3(12 Pt 1):2465?9.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"CR20","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/bcr658","volume":"6","author":"ME Robson","year":"2004","unstructured":"Robson ME, Chappuis PO, Satagopan J et al.A combined analysis of outcome following breast cancer:differences in survival based on BRCA1\/BRCA2 mutation status and administration of adjuvant treatment.Breast Cancer Res 2004;6(1):R8?R17.","journal-title":"Breast Cancer Res"},{"issue":"9245","key":"CR21","first-page":"1876","volume":"356","author":"SA Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P et al.Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers:a case-control study.Hereditary Breast Cancer Clinical Study Group.Lancet 2000;356(9245):1876?81.","journal-title":"Hereditary Breast Cancer Clinical Study Group.Lancet"},{"issue":"1","key":"CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng0597-17","volume":"16","author":"H Ozcelik","year":"1997","unstructured":"Ozcelik H, Schmocker B, Di Nicola N et al.Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients.Nat Genet 1997;16(1):17?8.","journal-title":"Nat Genet"},{"issue":"23","key":"CR23","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","volume":"94","author":"SA Narod","year":"2002","unstructured":"Narod SA, Dube MP, Klijn J et al.Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94(23):1773?9.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"CR24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrc726","volume":"2","author":"SA. Narod","year":"2002","unstructured":"Narod SA.Modifiers of risk of hereditary breast and ovarian cancer.Nat Rev Cancer 2002;2(2):113?23.","journal-title":"Nat Rev Cancer"},{"issue":"9193","key":"CR25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(99)04336-6","volume":"354","author":"H Jernstrom","year":"1999","unstructured":"Jernstrom H, Lerman C, Ghadirian P et al.Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.Lancet 1999;354(9193):1846?50.","journal-title":"Lancet"},{"issue":"3","key":"CR26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00001648-200205000-00004","volume":"13","author":"P Hartge","year":"2002","unstructured":"Hartge P, Chatterjee N, Wacholder S et al.Breast cancer risk in Ashkenazi BRCA1\/2 mutation carriers:effects of reproductive history.Epidemiology 2002;13(3):255?61.","journal-title":"Epidemiology"},{"issue":"10","key":"CR27","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/cncr.10949","volume":"95","author":"LA Quenneville","year":"2002","unstructured":"Quenneville LA, Phillips KA, Ozcelik H et al.HER-2\/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.Cancer 2002;95(10): 2068?75.","journal-title":"Cancer"},{"issue":"6","key":"CR28","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1073\/pnas.051624098","volume":"98","author":"E Levy-Lahad","year":"2001","unstructured":"Levy-Lahad E, Lahad A, Eisenberg S et al.A single nucleotide polymorphism in the RAD51 gene modi es cancer risk in BRCA2 but not BRCA1 carriers.Proc Natl Acad Sci USA 2001;98(6): 3232?6.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"CR29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ijc.11531","volume":"108","author":"L Kadouri","year":"2004","unstructured":"Kadouri L, Kote-Jarai Z, Easton DF et al.Polyglutamine repeat length in the AIB1 gene modi es breast cancer susceptibility in BRCA1 carriers.Int J Cancer 2004;108(3):399?403.","journal-title":"Int J Cancer"},{"issue":"20","key":"CR30","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","volume":"336","author":"JP Struewing","year":"1997","unstructured":"Struewing JP, Hartge P, Wacholder S et al.The risk of cancer associated with speci c mutations of BRCA1 and BRCA2 among Ashkenazi Jews.N Engl J Med 1997;336(20): 1401?08.","journal-title":"N Engl J Med"},{"issue":"5645","key":"CR31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB.Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.Science 2003; 302(5645):643?6.","journal-title":"Science"},{"issue":"4","key":"CR32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2003.05.096","volume":"21","author":"HT Lynch","year":"2003","unstructured":"Lynch HT, Snyder CL, Lynch JF et al.Hereditary breast-ovarian cancer at the bedside:role of the medical oncologist.J Clin Oncol 2003;21(4):740?53.","journal-title":"J Clin Oncol"},{"key":"CR33","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.J Clin Oncol 2003;21(12): 2397?2406.","DOI":"10.1200\/JCO.2003.03.189"},{"issue":"9","key":"CR34","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1073\/pnas.85.9.3044","volume":"85","author":"B Newman","year":"1988","unstructured":"Newman B, Austin MA, Lee M, King MC.Inheritance of human breast cancer:evidence for autosomal dominant trans-mission in high-risk families.Proc Natl Acad Sci USA 1988;85 (9):3044?8.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4988","key":"CR35","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.2270482","volume":"250","author":"JM Hall","year":"1990","unstructured":"Hall JM, Lee MK, Newman B et al.Linkage of early-onset familial breast cancer to chromosome 17q21.Science 1990;250 (4988):1684?9.","journal-title":"Science"},{"key":"CR36","unstructured":"Online Mendelian Inheritance in Man.Retrieved from http:\/\/ www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?db=OMIM on 15 March 2004."},{"key":"CR37","unstructured":"Breast Cancer Information Core (BIC).National Human Genome Research Institute.Retrieved from http:\/\/research.nhgri.nih.gov\/ bic\/on 15 March 2004."},{"issue":"5","key":"CR38","first-page":"1013","volume":"60","author":"CI Szabo","year":"1997","unstructured":"Szabo CI, King MC.Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60(5):1013?20.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"CR39","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE et al.Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals.J Clin Oncol2002;20(6):1480?90.","journal-title":"J Clin Oncol"},{"issue":"8","key":"CR40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/jmg.39.8.611","volume":"39","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Perez-Segura P, Robson ME et al.Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.J Med Genet2002;39(8):611?4.","journal-title":"J Med Genet"},{"issue":"3","key":"CR41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1399-0004.1998.tb04287.x","volume":"54","author":"A Liede","year":"1998","unstructured":"Liede A, Metcalfe K, Of t K et al.A family with three germline mutations in BRCA1 and BRCA2.Clin Genet1998;54(3):215?8.","journal-title":"Clin Genet"},{"issue":"4","key":"CR42","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1086\/302040","volume":"63","author":"E Friedman","year":"1998","unstructured":"Friedman E, Bar-Sade BR, Kruglikova A et al.Double hetero-zygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes.Am J Hum Genet1998;63(4):1224?7.","journal-title":"Am J Hum Genet"},{"key":"CR43","first-page":"405","volume":"26","author":"VA. Newill","year":"1961","unstructured":"Newill VA.Distribution of cancer mortality among etimic subgroups of the white population of New York City, 1953 ?58. J Natl Cancer Inst 1961;26:405?17.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"CR44","first-page":"1013","volume":"43","author":"EJ Salber","year":"1969","unstructured":"Salber EJ, Trichopulos D, MacMahon B.Lactation and repro-ductive histories of breast cancer patients in Boston, 1965 ?66. J Natl Cancer Inst1969;43(5):1013?24.","journal-title":"J Natl Cancer Inst"},{"issue":"9016","key":"CR45","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(96)91485-3","volume":"347","author":"KM Egan","year":"1996","unstructured":"Egan KM, Newcomb PA, Longnecker MP et al.Jewish religion and risk of breast cancer.Lancet1996;347(9016):1645?6.","journal-title":"Lancet"},{"issue":"9029","key":"CR46","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(05)65676-0","volume":"348","author":"PG Toniolo","year":"1996","unstructured":"Toniolo PG, Kato I.Jewish religion and risk of breast cancer. Lancet1996;348(9029):760.","journal-title":"Lancet"},{"key":"CR47","unstructured":"Jews and Medicine.Philadelphia\/Jerusalem:The Jewish Publica-tion Society, 1995."},{"issue":"6","key":"CR48","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ijc.2910640608","volume":"64","author":"SA Narod","year":"1995","unstructured":"Narod SA, Goldgar D, Cannon-Albright L et al.Risk modi ers in carriers of BRCA1 mutations.Int J Cancer 1995;64(6):394?8.","journal-title":"Int J Cancer"},{"issue":"5","key":"CR49","first-page":"272","volume":"123","author":"J Chang-Claude","year":"1997","unstructured":"Chang-Claude J, Becher H, Eby N et al.Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers.J Cancer Res Clin Oncol 1997;123(5):272?9.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"CR50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S et al.Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 muta-tions detected in case Series unselected for family history:a combined analysis of 22 studies.Am J Hum Genet 2003;72(5):1117?30.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"CR51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/gepi.1022","volume":"21","author":"N Chatterjee","year":"2001","unstructured":"Chatterjee N, Shih J, Hartge P et al.Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study. Genet Epidemiol 2001;21(2):123?38.","journal-title":"Genet Epidemiol"},{"issue":"6","key":"CR52","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/01.ede.0000083227.74669.7b","volume":"14","author":"JL Rutter","year":"2003","unstructured":"Rutter JL, Chatterjee N, Wacholder S, Struewing J.The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology2003;14(6):694?700.","journal-title":"Epidemiology"},{"issue":"4","key":"CR53","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.2910530403","volume":"53","author":"AJ Sasco","year":"1993","unstructured":"Sasco AJ, Lowenfels AB, Pasker-de Jong P.Review article: epidemiology of male breast cancer.A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993;53(4):538?49.","journal-title":"Int J Cancer"},{"issue":"8","key":"CR54","doi-asserted-by":"crossref","first-page":"678","DOI":"10.7326\/0003-4819-137-8-200210150-00013","volume":"137","author":"SH Giordano","year":"2002","unstructured":"Giordano SH, Buzdar AU, Hortobagyi GN.Breast cancer in men.Ann Intern Med 2002;137(8):678?87.","journal-title":"Ann Intern Med"},{"issue":"5","key":"CR55","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<744::AID-CNCR4>3.0.CO;2-G","volume":"86","author":"HT Lynch","year":"1999","unstructured":"Lynch HT, Watson P, Narod SA.The genetic epidemiology of male breast carcinoma.Cancer1999;86(5):744?6.","journal-title":"Cancer"},{"issue":"3","key":"CR56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M et al.Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families.The Breast Cancer Linkage Consortium.Am J Hum Genet1998;62(3):676?89.","journal-title":"Am J Hum Genet"},{"issue":"9?10","key":"CR57","first-page":"816","volume":"17","author":"R Steinitz","year":"1981","unstructured":"Steinitz R, Katz L, Ben Hur M.Male breast cancer in Israel: selected epidemiological aspects.Isr J Med Sci1981;17(9 ?10): 816?21.","journal-title":"Isr J Med Sci"},{"issue":"8","key":"CR58","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1002\/cncr.10449","volume":"94","author":"B Brenner","year":"2002","unstructured":"Brenner B, Fried G, Levitzki P et al.Male breast carcinoma in Israel:higher incident but possibly prognosis in Ashkenazi Jews. Cancer2002;94(8):2128?33.","journal-title":"Cancer"},{"key":"CR59","unstructured":"Friedman LS, Gayther SA, Kurosaki T et al.Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.Am J Hum Genet 1997;60 (2):313?9."},{"key":"CR60","doi-asserted-by":"crossref","unstructured":"Couch FJ, Farid LM, DeShano ML et al.BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13 (1):123 ?5.","DOI":"10.1038\/ng0596-123"},{"issue":"5","key":"CR61","first-page":"1079","volume":"60","author":"S Thorlacius","year":"1997","unstructured":"Thorlacius S, Sigurdsson S, Bjarnadottir H et al.Study of a single BRCA2 mutation with high carrier frequency in a small popula-tion.Am J Hum Genet 1997;60(5):1079?84.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"CR62","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1086\/302678","volume":"65","author":"JP Struewing","year":"1999","unstructured":"Struewing JP, Coriaty ZM, Ron E et al.Founder BRCA1\/2 mutations among male patients with breast cancer in Israel.Am J Hum Genet 1999;65(6):1800?02.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"CR63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","volume":"22","author":"A Liede","year":"2004","unstructured":"Liede A, Karlan BY, Narod SA.Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2:a review of the literature.J Clin Oncol 2004;22(4):735?42.","journal-title":"J Clin Oncol"},{"issue":"1","key":"CR64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","volume":"61","author":"DF Easton","year":"1997","unstructured":"Easton DF, Steele L, Fields P et al.Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13.Am J Hum Genet 1997;61(1):120?8.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"CR65","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1086\/316907","volume":"67","author":"A Liede","year":"2000","unstructured":"Liede A, Metcalfe K, Hanna D et al.Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling.Am J Hum Genet 2000;67(6):1494?504.","journal-title":"Am J Hum Genet"},{"issue":"15","key":"CR66","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.1997.03550150046034","volume":"278","author":"D Shattuck-Eidens","year":"1997","unstructured":"Shattuck-Eidens D, Oliphant A, McClure M et al.BRCA1 sequence analysis in women at high risk for susceptibility mutations.Risk factor analysis and implications for genetic testing.JAMA 1997;278(15):1242?50.","journal-title":"JAMA"},{"issue":"20","key":"CR67","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM199705153362002","volume":"336","author":"FJ Couch","year":"1997","unstructured":"Couch FJ, DeShano ML, Blackwood MA et al.BRCA1 muta-tions in women attending clinics that evaluate the risk of breast cancer.N Engl J Med 1997;336(20):1409?15.","journal-title":"N Engl J Med"},{"issue":"7","key":"CR68","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1200\/JCO.1998.16.7.2417","volume":"16","author":"TS Frank","year":"1998","unstructured":"Frank TS, Manley SA, Olopade OI et al.Sequence analysis of BRCA1 and BRCA2:correlation of mutations with family history and ovarian cancer risk.J Clin Oncol 1998;16(7):2417?25.","journal-title":"J Clin Oncol"},{"issue":"8","key":"CR69","first-page":"1082","volume":"16","author":"WS Rubinstein","year":"2002","unstructured":"Rubinstein WS, O'Neill SM, Peters JA et al.Mathematical modeling for breast cancer risk assessment.State of the art and role in medicine.Oncology (Huntingt)2002;16(8):1082?94.","journal-title":"Oncology (Huntingt)"},{"issue":"2","key":"CR70","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O","volume":"92","author":"AY Bahar","year":"2001","unstructured":"Bahar AY, Taylor PJ, Andrews L et al.The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews:implications for the generality of U.S.population data.Cancer2001;92(2):440?5.","journal-title":"Cancer"},{"key":"CR71","unstructured":"Whittemore AS, Gong G, Itnyre J.Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer:results from three U.S.population-based case-control studies of ovarian cancer.Am J Hum Genet 1997;60 (3):496?504."},{"issue":"4","key":"CR72","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/02841869609109913","volume":"35","author":"TI. Andersen","year":"1996","unstructured":"Andersen TI.Genetic heterogeneity in breast cancer susceptibility. Acta Oncol1996;35(4):407?10.","journal-title":"Acta Oncol"},{"issue":"11","key":"CR73","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","volume":"91","author":"J Peto","year":"1999","unstructured":"Peto J, Collins N, Barfoot R et al.Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst1999;91(11):943?9.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"CR74","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/302320","volume":"64","author":"P Hartge","year":"1999","unstructured":"Hartge P, Struewing JP, Wacholder S et al.The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet1999;64(4):963?70.","journal-title":"Am J Hum Genet"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJM199705153362003","volume":"336","author":"M Krainer","year":"1997","unstructured":"Krainer M, Silva-Arrieta S, Fitzgerald MG et al.Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.N Engl J Med1997;336(20):1416?21.","journal-title":"N Engl J Med"},{"issue":"1","key":"CR76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/301903","volume":"63","author":"FH Fodor","year":"1998","unstructured":"Fodor FH, Weston A, Bleiweiss IJ et al.Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.Am J Hum Genet 1998; 63(1):45?51.","journal-title":"Am J Hum Genet"},{"issue":"14","key":"CR77","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jnci\/91.14.1241","volume":"91","author":"E Warner","year":"1999","unstructured":"Warner E, Foulkes W, Goodwin P et al.Prevalence and pene-trance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancers.J Natl Cancer Inst 1999;91(14):1241?7.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"CR78","first-page":"505","volume":"60","author":"D Abeliovich","year":"1997","unstructured":"Abeliovich D, Kaduri L, Lerer I et al.The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60 % of ovarian cancer and 30 % of early-onset breast cancer patients among Ashkenazi women.Am J Hum Genet 1997; 60(3):505?14.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"CR79","first-page":"265","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT.Breast and ovarian cancer incidence in BRCA1-mutation carriers.Breast Cancer Linkage Consortiums.Am J Hum Genet 1995;56(1):265?71.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"CR80","first-page":"1059","volume":"60","author":"E Levy-Lahad","year":"1997","unstructured":"Levy-Lahad E, Catane R, Eisenberg S et al.Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel:frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.Am J Hum Genet 1997;60(5):1059?67.","journal-title":"Am J Hum Genet"},{"key":"CR81","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(98)03300-5","volume":"352","author":"S Thorlacius","year":"1998","unstructured":"Thorlacius S, Struewing JP, Hartge P et al.Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet1998;352(9137):1337?9.","journal-title":"Lancet"},{"key":"CR82","doi-asserted-by":"crossref","unstructured":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases.Anglian Breast Cancer Study Group.Br J Cancer2000;83(10):1301?8.","DOI":"10.1054\/bjoc.2000.1407"},{"issue":"3","key":"CR83","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DE et al.Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.Am J Hum Genet2001;68(3):700?10.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"CR84","first-page":"467","volume":"10","author":"JM Satagopan","year":"2001","unstructured":"Satagopan JM, Of t K, Foulkes W et al.The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Cancer Epidemiol Biomarkers Prev 2001;10(5):467?73.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"18","key":"CR85","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS, Rebbeck TR, Calzone KA et al.Cancer risk estimates for BRCA1 mutation carriers identi ed in a risk evaluation program.J Natl Cancer Inst2002;94(18):1365?72.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"CR86","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/jmg.39.6.407","volume":"39","author":"WD Foulkes","year":"2002","unstructured":"Foulkes WD, Brunet JS, Wong N et al.Change in the penetrance of founder BRCA1\/2 mutations?A retrospective cohort study. J Med Genet 2002;39(6):407?9.","journal-title":"J Med Genet"},{"key":"CR87","first-page":"3776","volume":"8","author":"JM Satagopan","year":"2002","unstructured":"Satagopan JM, Boyd J, Kauff ND et al.Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Clin Cancer Res 2002;8(12):3776?81.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"CR88","first-page":"741","volume":"8","author":"JL Hopper","year":"1999","unstructured":"Hopper JL, Southey MC, Dite GS et al.Population-based estimate of the average age-speci c cumulative risk of breast cancer for a de ned set of protein-truncating mutations in BRCA1 and BRCA2.Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8(9):741?7.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"16","key":"CR89","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/94.16.1221","volume":"94","author":"CB. Begg","year":"2002","unstructured":"Begg CB.On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst 2002; 94(16):1221?6.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"CR90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/gepi.10219","volume":"24","author":"G Gong","year":"2003","unstructured":"Gong G, Whittemore AS.Optimal designs for estimating pene-trance of rare mutations of a disease-susceptibility gene.Genet Epidemiol 2003;24(3):173?80.","journal-title":"Genet Epidemiol"},{"issue":"1","key":"CR91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1098-2272(1999)16:1<15::AID-GEPI3>3.0.CO;2-8","volume":"16","author":"MH Gail","year":"1999","unstructured":"Gail MH, Pee D, Benichou J, Carroll R.Designing studies to estimate the penetrance of an identi ed autosomal dominant mutation:cohort, case-control, and genotyped-proband designs. Genet Epidemiol1999;16(1):15?39.","journal-title":"Genet Epidemiol"},{"issue":"7","key":"CR92","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/aje\/148.7.623","volume":"148","author":"S Wacholder","year":"1998","unstructured":"Wacholder S, Hartge P, Struewing JP et al.The kin-cohort study for estimating penetrance.Am J Epidemiol1998;148(7):623?30.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"CR93","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1093\/jnci\/95.1.74","volume":"95","author":"CI. Amos","year":"2003","unstructured":"Amos CI.On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst2003;95(1):74?5.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"CR94","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jnci\/95.1.75","volume":"95","author":"PDP Pharoah","year":"2003","unstructured":"Pharoah PDP, Antoniou A, Hopper J, Easton D.On the use of familial aggregation in population-based case probands for calculating penetrances.J Natl Cancer Inst2003;95(1):75?6.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"CR95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jnci\/95.1.76","volume":"95","author":"AS Whittemore","year":"2003","unstructured":"Whittemore AS, Gong G.On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst2003;95(1):76?7.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"CR96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jnci\/95.1.77","volume":"95","author":"CB. Begg","year":"2003","unstructured":"Begg CB.On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst2003;95(1):77?8.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"CR97","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jnci\/95.1.78","volume":"95","author":"W Burke","year":"2003","unstructured":"Burke W, Austin M.On the use of familial aggregation in population-based case probands for calculating penetrance.J Natl Cancer Inst2003;95(1):78?9.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"CR98","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.GIM.0000055197.23822.5E","volume":"5","author":"TM Frezzo","year":"2003","unstructured":"Frezzo TM, Rubinstein WS, Dunham D, Ormond KE.The genetic family history as a risk assessment tool in internal medicine.Genet Med2003;5(2):84?91.","journal-title":"Genet Med"},{"issue":"24","key":"CR99","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/jnci\/95.24.1816","volume":"95","author":"T. Reynolds","year":"2003","unstructured":"Reynolds T.Study clari es risk of breast, ovarian cancer among mutation carriers.J Natl Cancer Inst2003;95(24):1816?8.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"CR100","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ijc.11271","volume":"106","author":"S de Sanjose","year":"2003","unstructured":"de Sanjose S, Leone M, Berez V et al.Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients:a population-based study.Int J Cancer2003;106(4):588?93.","journal-title":"Int J Cancer"},{"key":"CR101","unstructured":"Principles of Screening:Report of The Subcommittee on Screen-ing of the American College of Medical Genetics Clinical Practice Committee.20 March 0004."},{"issue":"2","key":"CR102","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2002.20.2.514","volume":"20","author":"MD Schwartz","year":"2002","unstructured":"Schwartz MD, Peshkin BN, Hughes C et al.Impact of BRCA1\/ BRCA2 mutation testing on psychologic distress in a clinic-based sample.J Clin Oncol2002;20(2):514?20.","journal-title":"J Clin Oncol"},{"issue":"1","key":"CR103","first-page":"79","volume":"11","author":"EA Peterson","year":"2002","unstructured":"Peterson EA, Milliron KJ, Lewis KE et al.Health insurance and discrimination concerns and BRCA1\/2 testing in a clinic popu-lation.Cancer Epidemiol Biomarkers Prev2002;11(1):79?87.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"CR104","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajmg.a.20025","volume":"120A","author":"K Armstrong","year":"2003","unstructured":"Armstrong K, Weber B, FitzGerald G et al.Life insurance and breast cancer risk assessment:adverse selection, genetic testing decisions, and discrimination.Am J Med Genet2003;120A(3):359?64.","journal-title":"Am J Med Genet"},{"issue":"4","key":"CR105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00125817-200007000-00003","volume":"2","author":"MA Hall","year":"2000","unstructured":"Hall MA, Rich SS.Patients' fear of genetic discrimination by health insurers:the impact of legal protections.Genet Med2000;2 (4):214?21.","journal-title":"Genet Med"},{"issue":"1","key":"CR106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/302714","volume":"66","author":"MA Hall","year":"2000","unstructured":"Hall MA, Rich SS.Laws restricting health insurers' use of genetic information:impact on genetic discrimination.Am J Hum Genet 2000;66(1):293?307.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"CR107","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.1999.17.2.494","volume":"17","author":"VR Grann","year":"1999","unstructured":"Grann VR, Whang W, Jacobson JS et al.Bene ts and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol1999;17(2):494?500.","journal-title":"J Clin Oncol"},{"issue":"5","key":"CR108","first-page":"475","volume":"10","author":"WF Lawrence","year":"2001","unstructured":"Lawrence WF, Peshkin BN, Liang W et al.Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations.Cancer Epidemiol Biomarkers Prev2001; 10(5):475?81.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"CR109","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/pon.531","volume":"10","author":"KP Tercyak","year":"2001","unstructured":"Tercyak KP, Peshkin BN, Streisand R, Lerman C.Psycholog-ical issues among children of hereditary breast cancer gene (BRCA1\/2)testing participants.Psychooncology2001;10(4):336?46.","journal-title":"Psychooncology"},{"issue":"2","key":"CR110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/ajmg.10110","volume":"107","author":"C Hughes","year":"2002","unstructured":"Hughes C, Lerman C, Schwartz M et al.All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results.Am J Med Genet 2002;107(2):143?50.","journal-title":"Am J Med Genet"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-004-9550-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-004-9550-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-004-9550-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:45:53Z","timestamp":1559238353000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-004-9550-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":110,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2004]]}},"alternative-id":["5379550"],"URL":"https:\/\/doi.org\/10.1007\/s10689-004-9550-2","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"value":"1389-9600","type":"print"},{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}